
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is positioned favorably due to its innovative approach in developing stenoparib, which has demonstrated significant clinical benefits for patients with advanced recurrent ovarian cancer and limited treatment options. The company's proprietary Drug Response Predictor (DRP) technology enhances patient selection, potentially leading to improved outcomes that could drive revenue growth. Current valuations suggest an attractive investment opportunity, with a notable upside anticipated based on net present value (NPV) analysis, indicating a promising financial horizon for the company's stock.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.37 million, translating to an earnings per share (EPS) of $(0.15), which fell short of estimates by $(0.06), highlighting ongoing financial challenges. The company's outlook is further strained by significant risks including potential balance sheet and liquidity issues, along with the possibility that its product candidates may fail to demonstrate necessary safety and efficacy in clinical trials and post-market settings. Additional concerns arise from the competitive landscape, regulatory hurdles, and changing macroeconomic factors that may impede growth and investor sentiment towards the biotech sector.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares